Multiple Myeloma

Expert faculty review and share their insights on key findings in multiple myeloma presented at the 2023 ASH Annual Meeting.

Share

Program Content

Activities

  • Multiple Myeloma
    Conference to Clinic: Multiple Myeloma
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 09, 2024

  • ASH 2023 Multiple Myeloma
    Conference to Clinic: Expert Analysis of the Top Multiple Myeloma Abstracts From the 2023 ASH Annual Meeting
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 07, 2024

    Expires: March 06, 2025

Activities

CENTAURUS Final Analysis
CENTAURUS: Final Analysis of Phase II Study With Daratumumab Monotherapy in Intermediate- or High-Risk Smoldering MM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2023

VenDd in t(11;14) RR MM
Phase I/II Trial of Venetoclax/Dara/Dex (VenDd) vs Bortezomib/Dara/Dex (DVd) in t(11;14) R/R MM: Updated Analysis of MRD Negativity
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2023

IsKia EMN24 in ND MM
IsKia EMN24: Phase III Trial of IsaKRd vs KRd in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

DRVd vs RVd Real World
D-RVd vs RVd for Newly Diagnosed Transplant-Eligible Patients With Multiple Myeloma: Real-world Outcomes
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

PERSEUS Primary Analysis
PERSEUS: Primary Analysis of Phase III Trial With VRd ± Daratumumab in Patients With Newly Diagnosed Multiple Myeloma Eligible for ASCT
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

LINKER-MM1 Update
LINKER-MM1 Update: Phase I/II Trial of Anti-BCMAxCD3 Bispecific Antibody Linvoseltamab in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

MonumenTAL-1 Modified Dosing
MonumenTAL-1: Impact of Dose Modification on Safety and Efficacy of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2023

Faculty

cover img faculity

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Provided by

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.